Last 47 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.33 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.77 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 27.76 | — | 68.45 | 62.80 | 89.30 | 54.87 | 72.77 | 55.35 | 65.63 | 42.34 | 77.53 | 58.04 | 72.01 | 89.67 | 92.00 | 99.84 | 149.29 | 151.92 | 287.55 | 190.24 | 269.63 |
| — | — | -5.9% | +13.5% | +36.1% | +29.6% | -6.1% | -4.6% | -8.9% | -52.8% | -15.7% | -41.9% | -51.8% | -41.0% | -68.0% | -47.5% | -44.6% | -54.8% | -19.9% | — | — | |
| P/B Ratio | 0.12 | 1.40 | 0.87 | 0.72 | 1.29 | 0.80 | 1.31 | 0.79 | 0.70 | 0.51 | 1.06 | 0.68 | 0.69 | 0.78 | 0.70 | 0.70 | 0.91 | 1.39 | 2.44 | 1.51 | 1.92 |
| — | +73.5% | -33.6% | -9.4% | +84.2% | +57.0% | +23.8% | +17.0% | +0.7% | -34.3% | +50.4% | -2.7% | -23.7% | -44.0% | -71.2% | -54.0% | -52.6% | -78.4% | -58.2% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -1128.9% | — | -1377.1% | -14.8% | -14.8% | 91.9% | 91.9% | -2118.3% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% |
| — | — | -1598.4% | +99.3% | -116.1% | 0.0% | 0.0% | -2404.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +0.0% | -4.6% | +116.5% | +213.7% | |
| Operating Margin | -5937.0% | — | -8846.4% | -4363.3% | -6388.2% | -6926.8% | -6069.7% | -10414.2% | -5603.6% | -5563.2% | -4879.1% | -6455.8% | -4290.7% | -6185.8% | -4457.4% | -9192.0% | -5265.8% | -2742.2% | -3344.7% | -5228.1% | -2573.9% |
| — | — | -45.7% | +58.1% | -14.0% | -24.5% | -24.4% | -61.3% | -30.6% | +10.1% | -9.5% | +29.8% | +18.5% | -125.6% | -33.3% | -75.8% | -104.6% | -13.2% | +36.2% | -48.2% | +34.1% | |
| Net Margin | -5863.5% | — | -9137.5% | -4890.3% | -6160.5% | -6681.2% | -5721.9% | -9600.7% | -5152.9% | -5169.4% | -4447.3% | -6219.8% | -3662.5% | -5619.7% | -5028.3% | -9224.6% | -5454.9% | -3652.7% | -3351.1% | -6039.5% | 35423.7% |
| — | — | -59.7% | +49.1% | -19.6% | -29.2% | -28.7% | -54.4% | -40.7% | +8.0% | +11.6% | +32.6% | +32.9% | -53.8% | -50.0% | -52.7% | -115.4% | -42.5% | +38.1% | -69.2% | +1010.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -74.6% | -15.8% | -27.5% | -15.6% | -22.4% | -27.0% | -22.8% | -29.3% | -14.6% | -16.6% | -14.0% | -16.4% | -8.4% | -11.4% | -9.2% | -15.0% | -10.0% | -8.0% | -6.9% | -11.3% | 91.8% |
| — | +41.6% | -20.5% | +46.8% | -53.4% | -62.9% | -63.1% | -78.6% | -74.4% | -45.1% | -52.6% | -9.4% | +16.1% | -42.0% | -33.2% | -32.2% | -110.9% | +30.4% | +79.6% | +76.0% | +445.7% | |
| ROA | -56.3% | -12.8% | -22.5% | -12.6% | -17.0% | -19.2% | -15.5% | -21.7% | -11.2% | -12.4% | -10.9% | -13.4% | -6.9% | -9.5% | -8.0% | -13.5% | -8.9% | -7.0% | -6.0% | -10.0% | 77.9% |
| — | +33.1% | -45.4% | +41.8% | -52.3% | -54.2% | -42.0% | -61.6% | -63.0% | -30.6% | -36.5% | +0.5% | +22.9% | -35.7% | -33.8% | -35.3% | -111.4% | +20.2% | +77.7% | +77.1% | +407.3% | |
| ROIC | -239.1% | -41.1% | -71.7% | -44.6% | -103.1% | -128.5% | -81.9% | -92.3% | -44.9% | -36.9% | -25.0% | -17.5% | -7.5% | -13.0% | -32.1% | — | — | — | — | — | — |
| — | +68.0% | +12.5% | +51.7% | -129.6% | -248.1% | -227.8% | -426.2% | -497.6% | -185.0% | +22.2% | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 11.36 | 5.36 | 9.65 | 11.36 | 8.70 | 6.07 | 4.73 | 4.29 | 7.91 | 5.84 | 7.87 | 9.90 | 13.14 | 9.09 | 14.96 | 26.52 | 41.36 | 33.28 | 32.85 | 21.23 | 39.88 |
| — | -11.7% | +104.2% | +164.6% | +10.1% | +3.9% | -39.9% | -56.6% | -39.8% | -35.7% | -47.4% | -62.7% | -68.2% | -72.7% | -54.5% | +24.9% | +3.7% | +76.7% | +96.0% | +110.9% | +133.2% | |
| Quick Ratio | 11.36 | 5.36 | 9.65 | 11.36 | 8.70 | 6.07 | 4.73 | 4.29 | 7.91 | 5.84 | 7.87 | 9.90 | 13.14 | 9.09 | 14.96 | 26.52 | 41.36 | 33.28 | 32.85 | 21.23 | 39.88 |
| — | -11.7% | +104.2% | +164.6% | +10.1% | +3.9% | -39.9% | -56.6% | -39.8% | -35.7% | -47.4% | -62.7% | -68.2% | -72.7% | -54.5% | +24.9% | +3.7% | +78.7% | +97.6% | +115.9% | +136.7% | |
| Interest Coverage | -112.34 | -345.12 | -487.32 | -25.96 | -1252.32 | -729.76 | -498.24 | -6548.36 | -858.22 | -500.23 | -427.70 | -3850.93 | -611.39 | -542.72 | -546.67 | -870.62 | — | — | — | -6444.40 | -1022.65 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SILO stock.
Silo Pharma, Inc.'s current P/E is -0.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Silo Pharma, Inc.'s current operating margin is -5937.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Silo Pharma, Inc.'s business trajectory between earnings reports.